Mitonafide

Research use only, not for human use.

Mitonafide suppresses the activity of M. tuberculosis NAD+ dependent DNA ligase A. Mitonafide is a DNA intercalating agent.

Mitonafide suppresses the activity of M. tuberculosis NAD+ dependent DNA ligase A. Mitonafide is a DNA intercalating agent.

——

Mitonafide (0.5 and 1 mg/kg, i.p., 1-7 days) shows antitumoral potency in S-180 bearing mice.Mitonafide (5 mg/kg, i.p., twice a day) shows anticancer activity in HepG2 xenograft model.Mitonafide (single i.p. injection, S-180 bearing mice) shows the LD50 value of 10.0 mg/kg. Animal Model:S-180 bearing mice Dosage:0.5 mg/kg and 1 mg/kg Administration:Intraperitoneal injection (i.p.) for 1-7 days Result:Increased in median survival times.Animal Model:HepG2 xenograft model Dosage:5 mg/kg Administration:Intraperitoneal injection (i.p.), twice a day.Result:Exhibited a relative tumor increment rates (T/C) value of 28.8%.

NSC300288 | NSC-300288 | NSC 300288 | Mitonafide

GPCR/G Protein

Antibacterial

ATP citrate lyase|GPR40|GPR120

——

——

54824-17-8

313.313

C16H15N3O4

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (199.48 mM)

CN(C)CCN1C(=O)c2cccc3cc(cc(C1=O)c23)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years